Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | Improving accessibility and affordability of myeloma therapies

Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC, talks on the accessibility and affordability of optimal therapies for patients with multiple myeloma. In particular, Dr Usmani comments on the need for innovation and partnerships between academic institutions and pharmaceuticals companies to reduce the cost of care in myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Disclosures

Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx, Takeda; and has received speaking fees from Celgene, Janssen, Sanofi, Takeda.